Paper Details

  1. Home
  2. Paper Details

Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats.

Author: AbramjukClaudia, JuchemRolf, JungKlaus, KrellHans-Willi, LeinMichael, LoeningStefan A, PetersRobert, SchnorrJoerg, StaackAndrea, StephanCarsten, TaymoorianKasra

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the efficacy of Ro 28-2653, a matrix metalloproteinase (MMP) inhibitor, in combination with estramustine for treating prostate cancer in rats. The study found that Ro 28-2653 reduced tumor growth, and the combination therapy with estramustine showed further improvement. This suggests that Ro 28-2653 could be a viable treatment option for patients with prostate cancer.
Paper Details　
Original Abstract of the Article :
Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor, Ro 28-2653 (5-biphenyl-4-yl-5-[4-(-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione), has been shown in various models of different tumor entities. The tumor growth-reducing effect has been demonstrated in the orthotopi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/01.cad.0000173477.05358.ec

データ提供：米国国立医学図書館（NLM）

Matrix Metalloproteinase Inhibitor Ro 28-2653 in Combination with Estramustine for Prostate Cancer

In the relentless battle against cancer, researchers are constantly exploring innovative treatment strategies. This study investigates the potential of a novel matrix metalloproteinase (MMP) inhibitor, Ro 28-2653, in combination with estramustine, a hormone-sensitive prostate cancer medication. The study utilized an orthotopic rat prostate Dunning tumor model to assess the efficacy of this combined therapy.

The Potential of MMP Inhibition in Prostate Cancer

The results demonstrate that Ro 28-2653, when combined with estramustine, significantly reduced tumor growth in the rat model. This finding suggests that MMP inhibition may represent a promising therapeutic strategy for prostate cancer, particularly in hormone-sensitive cases.

New Avenues for Prostate Cancer Treatment

This research opens new avenues for the treatment of prostate cancer, highlighting the potential of MMP inhibition in combination with existing therapies. It's like finding a new oasis in the vast desert of cancer research, offering a potential source of relief and hope for patients battling this disease.

Dr.Camel's Conclusion

This study provides valuable insights into the potential of MMP inhibition as a therapeutic strategy in prostate cancer. The combination of Ro 28-2653 and estramustine demonstrated significant tumor growth reduction in a rat model, suggesting a promising avenue for future clinical investigation. It's a testament to the ongoing quest for effective and targeted therapies in the fight against this challenging disease. It's like discovering a new and fertile oasis in the vast desert of cancer research, offering a beacon of hope for patients and researchers alike.

Date :
  1. Date Completed 2005-11-22
  2. Date Revised 2019-09-17
Further Info :

Pubmed ID

16096433

DOI: Digital Object Identifier

10.1097/01.cad.0000173477.05358.ec

Related Literature

Article Analysis
・Effects of estramustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.